Literature DB >> 12704178

Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model.

Håvard Jakobsen1, Viktor D Sigurdsson, Sigurveig Sigurdardottir, Dominique Schulz, Ingileif Jonsdottir.   

Abstract

Immunization with a pneumococcal conjugate vaccine (PNC) containing serotype 19F induces cross-reactive antibodies to 19A in mice and human infants. Active immunization with PNC and passive immunization with serum samples from infants vaccinated with PNC containing serotype 19F, but not serotype 19A, protected against lung infection caused by both serotypes in a murine model.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12704178      PMCID： PMC153277          DOI： 10.1128/IAI.71.5.2956-2959.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  31 in total

1.  Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae.

Authors:  M H Nahm; J V Olander; M Magyarlaki
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

2.  Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.

Authors:  H R Shinefield; S Black; P Ray; I Chang; N Lewis; B Fireman; J Hackell; P R Paradiso; G Siber; R Kohberger; D V Madore; F J Malinowski; A Kimura; C Le; I Landaw; J Aguilar; J Hansen
Journal:  Pediatr Infect Dis J       Date:  1999-09       Impact factor: 2.129

3.  Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.

Authors:  R Dagan; R Melamed; O Zamir; O Leroy
Journal:  Pediatr Infect Dis J       Date:  1997-11       Impact factor: 2.129

4.  Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.

Authors:  N Mbelle; R E Huebner; A D Wasas; A Kimura; I Chang; K P Klugman
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

5.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; E Saeland; S Gizurarson; D Schulz; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

6.  Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory.

Authors:  H Ahman; H Käyhty; H Lehtonen; O Leroy; J Froeschle; J Eskola
Journal:  Pediatr Infect Dis J       Date:  1998-03       Impact factor: 2.129

7.  A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children.

Authors:  S K Obaro; Z Huo; W A Banya; D C Henderson; M A Monteil; A Leach; B M Greenwood
Journal:  Pediatr Infect Dis J       Date:  1997-12       Impact factor: 2.129

8.  Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants.

Authors:  X Yu; B Gray; S Chang; J I Ward; K M Edwards; M H Nahm
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

9.  Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants.

Authors:  H Ahman; H Käyhty; P Tamminen; A Vuorela; F Malinoski; J Eskola
Journal:  Pediatr Infect Dis J       Date:  1996-02       Impact factor: 2.129

10.  Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model.

Authors:  G S Giebink; J D Meier; M K Quartey; C L Liebeler; C T Le
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226
View more
  8 in total

1.  Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.

Authors:  Margret Y Richter; Havard Jakobsen; Jean-François Haeuw; Ultan F Power; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  Polysaccharide Capsule Composition of Pneumococcal Serotype 19A Subtypes Is Unaltered among Subtypes and Independent of the Nutritional Environment.

Authors:  Silvio D Brugger; Lukas J Troxler; Susanne Rüfenacht; Pascal M Frey; Brigitte Morand; Rudolf Geyer; Kathrin Mühlemann; Stefan Höck; Wolfgang Thormann; Julien Furrer; Stephan Christen; Markus Hilty
Journal:  Infect Immun       Date:  2016-10-17       Impact factor: 3.441

3.  Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Authors:  Margret Y Richter; Håvard Jakobsen; Alda Birgisdottir; Jean-François Haeuw; Ultan F Power; Giuseppe Del Giudice; Antonella Bartoloni; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.

Authors:  Hyunju Lee; Moon H Nahm; Robert Burton; Kyung-Hyo Kim
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

Review 5.  Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

Authors:  William P Hausdorff; Bernard Hoet; Lode Schuerman
Journal:  BMC Pediatr       Date:  2010-02-02       Impact factor: 2.125

6.  Immune response to 19A serotype after immunization of 19F containing pneumococcal conjugate vaccine in Korean children aged 12-23 months.

Authors:  Hyun Ju Lee; So Eun Park; Kyung Hyo Kim
Journal:  Korean J Pediatr       Date:  2011-04-30

Review 7.  Serotype distribution of invasive, non-invasive and carried Streptococcus pneumoniae in Malaysia: a meta-analysis.

Authors:  Alex J J Lister; Cheng Foh Le; Eddy Seong Guan Cheah; Mohd Nasir Mohd Desa; David W Cleary; Stuart C Clarke
Journal:  Pneumonia (Nathan)       Date:  2021-05-25

Review 8.  Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.

Authors:  Michael R Yeaman; Scott G Filler; Clint S Schmidt; Ashraf S Ibrahim; John E Edwards; John P Hennessey
Journal:  Front Immunol       Date:  2014-09-26       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.